Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $351.77M rose 2.2% year over year, behind the +10.3% change in trailing-twelve-month revenue. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at +16.8% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $1.45B (+0.3%) for the fiscal year ending Dec 2026, a slowdown from the +17.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$351.77M+4.5% QoQ
Last fiscal yearDec 2025
$1.45B+17.9% YoY
LTMJun 2026
$1.46B+10.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%-3.1%-5.3 pp
1 year+17.9%+0.3%-17.7 pp
3-year CAGR+16.8%+5.4%-11.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
1.45B USD
Year-over-year change
+17.9%
4-year CAGR
+16.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 revenue of $1.46B is the 4th highest of the 11 companies compared; the peer median is $390.73M.
  • Its year-over-year change of +10.3% is the 6th highest of 10, against a peer median of +22.0%.
  • Over three fiscal years its annual growth of +16.8% compares with a peer median of +9.9%.
GRDN Competitors Peer median
Revenue for GRDN and competitors
Company Period LTM YoY 3-year CAGR
QDELQuidelOrtho CorporationLTM Mar 2026$2.66B -3.9%-5.8%
MDPediatrix Medical Group, Inc.LTM Sep 2026$1.96B +1.9%-1.0%
NHCNational HealthCare CorporationLTM Sep 2026$1.58B +5.6%+12.2%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$1.46B +10.3%+16.8%
TXG10x Genomics, Inc.LTM Sep 2026$618.58M -3.6%+7.6%
TWSTTwist Bioscience CorporationLTM Sep 2026$459.43M +22.0%+23.3%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$322.02M +29.3%+60.1%
NUVBNuvation Bio Inc.LTM Jun 2026$169.9M +1083.6%—
MESOMesoblast LimitedLTM Jun 2026$120.25M +599.2%+152.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$21.61M +131.5%+5.1%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$0 ——
Peer median (excluding GRDN) $390.73M+22.0%+9.9%

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue792.07M908.91M1.05B1.23B1.45B
Cost of Revenue630.81M723.04M837.88M984.04M1.17B
Gross Profit161.27M185.87M208.31M244.37M282.04M
Gross Margin20.4%20.4%19.9%19.9%19.5%
Research & Development00000
Selling, General & Admin131.12M133.88M167.36M307.29M193.13M
Operating Expenses131.12M133.88M167.36M307.29M193.13M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
EBITDA46.49M68.15M58.81M(43.43M)96.42M
EBITDA Margin5.9%7.5%5.6%-3.5%6.7%
Operating Income30.15M51.99M40.95M(62.92M)88.91M
Operating Margin3.8%5.7%3.9%-5.1%6.1%
Interest Income00000
Interest Expense1.64M1.93M2.86M3.28M665K
Other Income / Expenses(1.82M)(2.33M)(3.23M)(3.56M)(15.49M)
Income Before Tax28.33M49.66M37.72M(66.48M)73.42M
Pre-Tax Margin3.6%5.5%3.6%-5.4%5.1%
Income Tax Expense0004.56M24.47M
Net Income16.31M35.42M23.9M(87.29M)49.22M
Net Margin2.1%3.9%2.3%-7.1%3.4%
EPS (Basic)0.270.580.39(1.77)0.79
EPS (Diluted)0.270.580.39(1.77)0.78
Weighted Avg Shares60.84M60.84M60.84M62.01M62.39M
Weighted Avg Shares (Diluted)60.84M60.84M60.84M62.01M63.3M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.